Efficacy and Safety of Ibrutinib in Indian Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma: Cases from a Named Patient Program

CONTEXT: This named patient program evaluated the safety and efficacy of ibrutinib, a selective inhibitor of Bruton's tyrosine kinase in Indian patients with relapsed/refractory chronic lymphocytic leukemia (CLL, with/without chromosome 17 deletion [del17p]) and mantle cell lymphoma (MCL). SUBJ...

Descripción completa

Detalles Bibliográficos
Autores principales: Agarwal, Mohan B, Bhurani, Dinesh, Shah, Chirag, Sood, Nitin, Singhal, Manish, Kamat, Anil, Chezhian, Subash, Mishra, Suryaprakash, Nagrale, Dinesh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2017
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5759073/
https://www.ncbi.nlm.nih.gov/pubmed/29333021
http://dx.doi.org/10.4103/ijmpo.ijmpo_43_17

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5759073/
https://www.ncbi.nlm.nih.gov/pubmed/29333021
http://dx.doi.org/10.4103/ijmpo.ijmpo_43_17

Ejemplares similares